TGF-β, to target or not to target; to prevent thyroid cancer progression?

Biochim Biophys Acta Rev Cancer

Biosciences Institute, Newcastle University, International Centre for Life, Central Parkway, Newcastle Upon Tyne, UK. Electronic address:

Published: July 2022


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Thyroid cancer (TC) is a common endocrine cancer with a rising incidence. Current treatment fails to eliminate aggressive thyroid tumours, prompting an investigation into the processes that cause disease progression. In this review, we provide insight into TGF-β driven epithelial to mesenchymal transition (EMT), summarizing the current literature surrounding thyroid carcinogenesis, and discuss the potential for therapeutic strategies targeting the TGF-β signalling pathway. Understanding the underlying mechanisms that regulate cancer stem cell (CSC) growth and TGF-β signalling may provide novel therapeutic approaches for highly resistant TCs.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbcan.2022.188752DOI Listing

Publication Analysis

Top Keywords

thyroid cancer
8
tgf-β signalling
8
tgf-β
4
tgf-β target
4
target target
4
target prevent
4
thyroid
4
prevent thyroid
4
cancer
4
cancer progression?
4

Similar Publications

Nuclear receptors (NRs) are a superfamily of ligand-activated transcription factors that regulate gene expression in response to metabolic, hormonal, and environmental signals. These receptors play a critical role in metabolic homeostasis, inflammation, immune function, and disease pathogenesis, positioning them as key therapeutic targets. This review explores the mechanistic roles of NRs such as PPARs, FXR, LXR, and thyroid hormone receptors (THRs) in regulating lipid and glucose metabolism, energy expenditure, cardiovascular health, and neurodegeneration.

View Article and Find Full Text PDF

Background: Thyroid nodules (TNs) are frequent and often benign. Accurately differentiating between benign and malignant nodules is crucial for proper management. This research aims to use ultrasonography to examine TNs and identify possible risk factors in order to improve patient outcomes and diagnostic accuracy.

View Article and Find Full Text PDF

Transcriptional condensates enrich phosphorylated PRMT2 to stimulate H3R8me2a deposition and hypoxic response in glioblastoma.

Sci China Life Sci

September 2025

State Key Laboratory of Experimental Hematology, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Tianjin Medical University Cancer Institute and Hospital, Tianjin Key Labora

Histone arginine methylation by protein arginine methyltransferases (PRMTs) is crucial for transcriptional regulation and is implicated in cancers. Despite their therapeutic potential, some PRMTs present challenges as drug targets due to their context-dependent activities. Here, we demonstrate that hypoxia triggers the rapid condensation of PRMT2, which is essential for its histone H3R8 asymmetric dimethylation (H3R8me2a) activity.

View Article and Find Full Text PDF

In recent years, there has been a rapid increase in the incidence of thyroid carcinoma (TC). Our study focuses on the regulatory effect of circular RNAs on metabolism of TC, aiming to provide new insights into the mechanisms of progression and a potential therapeutic target for TC. In this study, we identified high expression levels of circPSD3 in TC tissues through RNA sequencing.

View Article and Find Full Text PDF

Anaplastic thyroid cancer (ATC) is the most aggressive form of thyroid malignancy and currently lacks effective treatment options. While anti-PD1 therapy has shown remarkable clinical results in some cases, only a subset of ATC patients responds to it. Eganelisib (IPI549), a highly selective PI3Kγ inhibitor, can alleviate the tumor immunosuppressive state by reducing the proportion of M2-like tumor associated macrophages, partially overcoming patient resistance to anti-PD1 therapy and synergizing with its efficacy.

View Article and Find Full Text PDF